Abeona therapeutics® reports second quarter 2024 financial results and concludes type a meeting with fda to align on upcoming pz-cel bla resubmission

Significant progress addressing cmc items noted in crl bla resubmission remains on track for 2h 2024 cleveland, aug. 12, 2024 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today reported financial results for the second quarter of 2024 and recent corporate progress. “having completed data generation for nearly all of the chemistry manufacturing and controls deliverables outlined in the complete response letter that we received in april 2024, we are on track to resubmit our biologics license application for pz-cel this year and, if approved, bring a treatment option to patients with recessive dystrophic epidermolysis bullosa,” said vish seshadri, chief executive officer of abeona.
ABEO Ratings Summary
ABEO Quant Ranking